Wall Street brokerages expect Henry Schein, Inc. (NASDAQ:HSIC) to report $0.92 earnings per share for the current quarter, Zacks reports. Nine analysts have issued estimates for Henry Schein’s earnings, with estimates ranging from $0.91 to $0.95. Henry Schein reported earnings per share of $0.88 during the same quarter last year, which would indicate a positive year over year growth rate of 4.5%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Henry Schein will report full year earnings of $4.08 per share for the current financial year, with EPS estimates ranging from $3.99 to $4.14. For the next year, analysts anticipate that the business will report earnings of $4.44 per share, with EPS estimates ranging from $4.12 to $4.55. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Henry Schein.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 20th. The company reported $0.97 earnings per share for the quarter, hitting the consensus estimate of $0.97. The company had revenue of $3.32 billion for the quarter, compared to the consensus estimate of $3.30 billion. Henry Schein had a return on equity of 19.70% and a net margin of 3.26%. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.94 EPS.
Henry Schein (NASDAQ HSIC) traded up $1.30 during trading on Wednesday, hitting $68.43. The company had a trading volume of 1,209,012 shares, compared to its average volume of 2,617,465. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.45 and a quick ratio of 0.76. The stock has a market cap of $10,317.49, a P/E ratio of 26.89, a P/E/G ratio of 1.65 and a beta of 1.09. Henry Schein has a 52 week low of $62.56 and a 52 week high of $93.50.
Hedge funds have recently added to or reduced their stakes in the stock. FTB Advisors Inc. lifted its position in Henry Schein by 100.0% in the 3rd quarter. FTB Advisors Inc. now owns 1,484 shares of the company’s stock valued at $120,000 after acquiring an additional 742 shares in the last quarter. Lee Financial Co lifted its position in Henry Schein by 100.0% in the 3rd quarter. Lee Financial Co now owns 1,756 shares of the company’s stock valued at $144,000 after acquiring an additional 878 shares in the last quarter. JNBA Financial Advisors lifted its position in Henry Schein by 100.0% in the 3rd quarter. JNBA Financial Advisors now owns 2,000 shares of the company’s stock valued at $164,000 after acquiring an additional 1,000 shares in the last quarter. Westside Investment Management Inc. lifted its position in Henry Schein by 100.0% in the 3rd quarter. Westside Investment Management Inc. now owns 2,000 shares of the company’s stock valued at $160,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Captrust Financial Advisors bought a new position in shares of Henry Schein during the 4th quarter valued at $141,000. 97.62% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3254081/0-92-earnings-per-share-expected-for-henry-schein-inc-nasdaqhsic-this-quarter.html.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.